TrialFrontiers in immunology2025

Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension.

Marc A Riedl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.